Manuel Guzmán

The paper identifies PCMT1 as an enzyme that forms C-terminal cyclic imides on CRBN substrates, linking it to metabolic enzyme regulation and epileptic phenotypes.

This study identifies CB1R overactivation as a driver of CRBN deficiency-linked ARNSID and suggests CB1R blockade as a potential therapy.

This study identifies FAAH as a key regulator of adult mammary gland development by promoting luminal cell differentiation through endocannabinoid signaling.

This study identifies D1R-H3R heteromers as a therapeutic target for Huntington’s disease by showing their role in dopamine signaling and their modulation by H3R antagonists.